Loading stock data…
AC Immune SA (ACIU)
$2.78-0.08 (-2.80%)
After Hours$2.78+0.00 (+0.00%)· Last close Sep 8
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AC Immune SA in the Healthcare sector is trading at $2.78 with a market capitalization of $284M. Wall Street consensus targets $8.53 (4 analysts), implying a +206.8% move over the next 12 months. The stock is currently 31% below its 52-week high of $4.00, remaining 1.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +206.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.11M↑ | $1.12M↑ | $338,000↓ | $939,000↓ | $1.31M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $1.19M↑ | -$14.79M↓ | -$14.41M↑ | -$15.70M↑ | -$19.39M |
| Net Income | $1.87M↑ | -$14.80M↓ | -$14.37M↑ | -$15.86M↑ | -$21.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$284.36M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-122.72%
Volume
Today's trading volume
100,863
Recent News
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.